FI113619B - Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi - Google Patents

Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi

Info

Publication number
FI113619B
FI113619B FI952680A FI952680A FI113619B FI 113619 B FI113619 B FI 113619B FI 952680 A FI952680 A FI 952680A FI 952680 A FI952680 A FI 952680A FI 113619 B FI113619 B FI 113619B
Authority
FI
Finland
Prior art keywords
compositions based
injectable compositions
taxane derivatives
preparing injectable
solutions
Prior art date
Application number
FI952680A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952680A0 (fi
FI952680L (fi
Inventor
Jean-Marc Bobee
Lanty Patrick De
Gilles Guerin
Michel Veillard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI113619(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI952680A0 publication Critical patent/FI952680A0/fi
Publication of FI952680L publication Critical patent/FI952680L/fi
Application granted granted Critical
Publication of FI113619B publication Critical patent/FI113619B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
FI952680A 1992-12-02 1995-06-01 Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi FI113619B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.
PCT/FR1993/001166 WO1994012171A1 (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes

Publications (3)

Publication Number Publication Date
FI952680A0 FI952680A0 (fi) 1995-06-01
FI952680L FI952680L (fi) 1995-06-01
FI113619B true FI113619B (fi) 2004-05-31

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952680A FI113619B (fi) 1992-12-02 1995-06-01 Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi

Country Status (28)

Country Link
US (1) US5438072A (cs)
EP (1) EP0671912B1 (cs)
JP (1) JP3689791B2 (cs)
KR (1) KR100330316B1 (cs)
CN (2) CN1090170A (cs)
AT (1) ATE190838T1 (cs)
AU (1) AU691476B2 (cs)
CA (1) CA2150576C (cs)
CZ (1) CZ284080B6 (cs)
DE (2) DE69328192D1 (cs)
DK (1) DK0671912T3 (cs)
ES (1) ES2145115T4 (cs)
FI (1) FI113619B (cs)
FR (1) FR2698543B1 (cs)
GE (1) GEP19991856B (cs)
GR (1) GR3032828T3 (cs)
HU (1) HU222833B1 (cs)
MX (1) MX9306986A (cs)
NO (1) NO314436B1 (cs)
NZ (1) NZ258150A (cs)
PL (1) PL174334B1 (cs)
PT (1) PT671912E (cs)
RU (1) RU2144356C1 (cs)
SK (1) SK281558B6 (cs)
TW (1) TW271395B (cs)
WO (1) WO1994012171A1 (cs)
YU (1) YU49092B (cs)
ZA (1) ZA938936B (cs)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ATE154757T1 (de) 1993-07-19 1997-07-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
ES2248847T3 (es) * 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
DE19655141C5 (de) 1996-11-08 2013-12-05 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
HUP0002922A3 (en) 1997-04-28 2003-03-28 Aventis Pharma Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
DE69716485T2 (de) * 1997-05-30 2003-04-10 Man Woo Han Taxol enthaltende pharmazeutische injektionslösung
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2003022248A1 (en) * 2001-09-13 2003-03-20 Korea Institute Of Science And Technology Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
ATE411036T1 (de) * 2001-10-19 2008-10-15 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
ES2369640T3 (es) 2002-05-24 2011-12-02 Angiotech International Ag Composiciones y métodos para revestir implantes médicos.
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2536242A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
PT1792927E (pt) * 2004-09-22 2013-05-15 Nippon Kayaku Kk Novo copolímero em bloco, preparação de micelas e agente anticancerígeno contendo o mesmo como ingrediente activo
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
WO2006133510A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
CN101448875A (zh) 2006-05-18 2009-06-03 日本化药株式会社 鬼臼毒素类的高分子量结合体
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
WO2008056596A1 (fr) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
JP2010524919A (ja) * 2007-04-23 2010-07-22 サン、ファーマスーティカル、インダストリーズ、リミテッド 医薬組成物
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
EP2206502B1 (en) 2007-09-28 2018-09-12 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of steroid
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
EP2205215A2 (en) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
EP2249825B1 (en) 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
AU2008352603B2 (en) 2008-03-14 2012-05-31 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
CA2716592C (en) 2008-03-18 2018-02-27 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PL2493466T3 (pl) 2009-10-29 2021-11-15 Sanofi Mature Ip Nowe przeciwguzowe zastosowanie kabazytakselu
CN104208716A (zh) * 2009-11-23 2014-12-17 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
AR079256A1 (es) 2009-12-04 2012-01-04 Genentech Inc Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
TW201304805A (zh) 2010-11-17 2013-02-01 Nippon Kayaku Kk 新穎之胞核苷系代謝拮抗劑之高分子衍生物
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
BR112013025353A8 (pt) 2011-04-01 2018-01-02 Genentech Inc combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
HRP20220319T1 (hr) 2011-05-19 2022-05-13 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Makrociklički spojevi kao inhibitori protein kinaze
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013266243A1 (en) 2012-05-24 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
KR101689946B1 (ko) 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2968406A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai WITH AUTOLOGOUS TUMORLYSAT-LOADED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN106459200B (zh) 2014-03-21 2019-12-06 艾伯维公司 抗-egfr抗体及抗体药物偶联物
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
KR102434626B1 (ko) 2016-06-08 2022-08-24 애브비 인코포레이티드 항-b7-h3 항체 및 항체 약물 콘쥬게이트
JP7317804B2 (ja) 2017-09-07 2023-07-31 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド ドセタキセル結合体の医薬組成物及び調製方法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
PL174334B1 (pl) 1998-07-31
JP3689791B2 (ja) 2005-08-31
CN1090170A (zh) 1994-08-03
JPH08503689A (ja) 1996-04-23
CN1291713C (zh) 2006-12-27
CA2150576A1 (fr) 1994-06-09
TW271395B (cs) 1996-03-01
DE69328192D1 (de) 2000-04-27
GEP19991856B (en) 1999-12-06
DE69328192T2 (de) 2000-09-28
FR2698543A1 (fr) 1994-06-03
MX9306986A (es) 1995-01-31
ES2145115T3 (es) 2000-07-01
NO952151D0 (no) 1995-05-31
RU2144356C1 (ru) 2000-01-20
YU74593A (sh) 1996-08-13
NO314436B1 (no) 2003-03-24
GR3032828T3 (en) 2000-06-30
ES2145115T4 (es) 2010-06-17
NZ258150A (en) 1996-11-26
AU691476B2 (en) 1998-05-21
PL309197A1 (en) 1995-09-18
EP0671912A1 (fr) 1995-09-20
HU9501596D0 (en) 1995-08-28
CA2150576C (fr) 2005-06-21
FR2698543B1 (fr) 1994-12-30
PT671912E (pt) 2000-06-30
EP0671912B1 (fr) 2000-03-22
HUT72650A (en) 1996-05-28
DE69328192T4 (de) 2007-07-19
ATE190838T1 (de) 2000-04-15
NO952151L (no) 1995-05-31
YU49092B (sh) 2003-12-31
CZ284080B6 (cs) 1998-08-12
HU222833B1 (hu) 2003-11-28
SK72595A3 (en) 1995-11-08
WO1994012171A1 (fr) 1994-06-09
ZA938936B (en) 1994-08-03
FI952680A0 (fi) 1995-06-01
DK0671912T3 (da) 2000-07-03
CN1636560A (zh) 2005-07-13
HK1075197A1 (en) 2005-12-09
KR100330316B1 (ko) 2002-11-04
SK281558B6 (sk) 2001-05-10
AU5566994A (en) 1994-06-22
US5438072A (en) 1995-08-01
KR950703946A (ko) 1995-11-17
CZ142195A3 (en) 1995-10-18
FI952680L (fi) 1995-06-01

Similar Documents

Publication Publication Date Title
FI113619B (fi) Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi
YU182691A (sh) Postupak za dobijanje derivata taksana i dobijeni novi derivati
FI921030A0 (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
FI931031A0 (fi) Mometasonfuroatmonohydrat, foerfarande foer dess framstaellning och farmaceutiska sammansaettningar
PL285248A1 (en) Method of obtaining novel aminophenol derivatives
ATE219061T1 (de) Huperzin a analoge verbindungen
FI952294L (fi) Menetelmä taksaanijohdannaisten valmistamiseksi, näin saadut uudet taksaanit ja niitä sisältävät kasvainvastaiset ja leukemiavastaiset koostumukset
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
BG32851A3 (bg) Метод за получаване на 3,4,5,6-тетрахидро-2н- -1-бензоксецини
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
NO981393D0 (no) Guanidinoproteasehemmere
DE69132578D1 (de) Cephemderivate
BG38637A3 (en) Method for preparing 2- exo- hydroxy- 7- oxabicyclo [2, 2, 1] heptanes
ES429871A1 (es) Procedimiento de preparacion de derivados 1, 3-benzodioxol.
FI884838A0 (fi) Nytt s-timololderivat och foerfarande foer dess framstaellning.
BG41129A3 (en) Method for preparing acetamide derivatives
DK0937057T3 (da) Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
JPS52138580A (en) Cyclodextrin derivatives
JPS51125722A (en) Germicides for industry and their preparation
JPS5283532A (en) Novel aromatic compounds
GB1288060A (cs)
BG35030A3 (en) Method for preparing bicyclo (2.2.1) heptanic derivatives
GB1504207A (en) Compositions containing p-alkanoyltoluene derivatives
BG29137A3 (en) Method of obtainpng of 6- alpha- deoxytetracyclin

Legal Events

Date Code Title Description
MA Patent expired